宫颈癌患者人乳头状瘤病毒感染情况

doi:10.3969/j.issn.1671-7171.2017.07.016

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨宫颈癌患者人乳头状瘤病毒(HPV)感染的分布及其规律。【方法】收集2012年1月至2015年7月南华大学附属第一医院宫颈癌患者346例,采用Luminex 200多功能流式点阵分析仪对HPV-DNA进行检测,对资料进行对比分析。【结果】346例宫颈癌患者中HPV感染阳性率为80.35%(278/346)。高危型 HPV感染率为79.77%(276/346),占HPV感染阳性率99.28%(276/278);HPV感染以单一型为主,占91.73%(255/278),2例为低危型;多重HPV感染患者中以两重HPV感染多见,占73.91%(17/23)。宫颈癌高发年龄段在40～49岁,总体分布上呈“双峰型”,但各年龄段HPV感染率比较差异无统计学意义(P＞0.05)。346例宫颈癌患者中,组织学分类明确有324例,其中宫颈鳞状细胞癌289例(89.20%,289/324),腺癌28例(8.64%,28/324),腺鳞癌7例(2.16%,7/324),以鳞癌多见,其次是腺癌、腺鳞癌,但不同病理组织学类型HPV感染率比较差异无统计学无意义(P＞0.05);不同组织学类型宫颈癌均以单一型HPV感染多见,鳞癌、腺癌、腺鳞癌中单一型HPV感染分别为214例(74.05%,214/289)、20例(71.43%,20/28)、5例(71.43%,5/7),HPV阴性患者分别有52例、8例、2例。【结论】宫颈癌患者中HPV感染最常见的是16型,接下来依次为18、58型、59及52型,33型、39及45型、31型,因此,需针对性研制包括HPV 16、18、58、59、52、33、39、45和31型在内的九价疫苗;不同年龄段宫颈癌患者HPV感染率差异无统计学意义;HPV 16主要与鳞癌有关,HPV 18则主要与腺癌和腺鳞癌有关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	郑海霞
	陈忠东
	杨捷

关键词 ：宫颈肿瘤, 乳头状瘤病毒科, 肿瘤病毒感染, 乳头状瘤病毒疫苗

Abstract：【Objective】To study the distribution of human papillomavirus (HPV) infection in patients with cervical cancer. 【Methods】A total of 346 cervical cancer patients from January 2012 to July 2015 in The First Affiliated Hospital of University of South China were collected for the study. Luminex 200 multifunction flow lattice analyzer (made in the United States) were used to detect HPV-DNA. The data were compared, analyzed ,and summarized. 【Results】The positive rate of HPV infection in 346 cases of cervical cancer was 80.35% (278/346), and HR-HPV infection accounted for 79.77% (276/346). The main HPV infection pattern was a single type infection (91.73%), and HPV type 16 was the most common HPV type,( 70.20%), followed by type 18 (10.98%), type 58 (5.10%),type 59 and 52 (3.14%),type 33(1.96%)、type 39 and 45(1.57%)、type 31(1.18%). The ages of cervical cancer patients with different HPV infection were different, but the incidence of HPV infection rate in each age groups was not statistically significant. Among the 346 cases of cervical cancer, 324 cases showed clear histological classification, including 289 cases of cervical squamous cell carcinoma (89.20%, 289/324), 28 cases of adenocarcinoma (8.64%, 28/324), and 7 cases of adenosquamous carcinoma (2.16%, 7/324). Squamous cell carcinoma is the most common, followed by adenocarcinoma and adenosquamous carcinoma. There were no significant difference in HPV infection rate among different histopathological types (P＞0.05). Cervical cancer with different histological diagnosis mainly showed one type of HPV infection (HPV infection rates in squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma were 74.05%, 71.43%,and 71.43%,irrespectively. HPV negative patients above were 52, 8 and 2 cases, irrespectively). 【Conclusion】HPV-16 is the most common HPV infection type, followed by HPV-18,58,59 and 52,33,39 and 45,and 31. Accordingly, vaccines including HPV type 16 combined with HPV type 18, 58, 59,52,33,39, 45,and 31 are necessary to prevent HPV infection. HPV-16 is mainly associated with cervical squamous cell carcinoma, while HPV-18 is mainly associated with adenocarcinoma and adenosquamous carcinoma.

Key words： Uterine Cervical Neoplasms Papillomaviridae Tumor Virus Infections Papillomavirus Vaccines

收稿日期: 2017-03-20

PACS:

R711.74

作者简介: 郑海霞, 研究生, 就读于南华大学

引用本文:

郑海霞,陈忠东,杨捷. 宫颈癌患者人乳头状瘤病毒感染情况[J]. 医学临床研究, 2017, 34(7): 1297-1299.
ZHENG Hai-xia, CHEN Zhong-dong, YANG Jie. Infection of Human Papillomavirus in Cervical Cancer Patients. JOURNAL OF CLINICAL RESEARCH, 2017, 34(7): 1297-1299.

链接本文:

http://www.jcr.net.cn/CN/10.3969/j.issn.1671-7171.2017.07.016 或 http://www.jcr.net.cn/CN/Y2017/V34/I7/1297

[1] Ferlay J, Soerjomataram I, Ervik M,et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015, 136(5):E359-386.
[2] Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015, 65(2):87-108.
[3] Zur Hausen H,Meinhcf W,Scheiber W,et al.Attempts to detect virus specific DNA sequence in human tumors:nucleic acid hybridization with complementary RNA of human wart virus[J].Int J Cancer,1976,13(5):650-659.
[4] 李欧.唐山地区高危型人乳头状瘤病毒感染与宫颈癌关系的调查研究[J].中华医院感染学杂志.2011.21(1):80-81.
[5] Garland SM. Can cervical cancer be eradicated by prophylactic HPV vaccination Challenges to vaccine implementation[J].Indian J Med Res,2009, 130(3):311-321.
[6] Chan PK.Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China[J].Int J Cancer, 2012,131(3):692-705.
[7] Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account[J].Virology,2009, 38(2):260-265.
[8] Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J].N Engl J Med,2015, 372 (8): 711-723.
[9] Guardado-Estrada M, Juárez-Torres E, Román-Bassaure E, et al.The distribution of high-risk human papillomaviruses is different in young and old patients with cervical cancer[J].PLoS One,2012, 9(10):e109406.
[10] Kane MA, Serrano B, de Sanjose S, et al. Implementation of human papillomavirus immunization in the developing world[J].Vaccine,2012, 30(Suppl 5): F192-200.
[11] Watson-Jones D,Baisley K,Brown J, et al.High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects[J].Sex Transm Infect,2013, 89(5):358-365.
[12] Vizcaino AP, Moreno V, Bosch FX, et al. International Trends in Incidence of Cervical Cancer: II Squamous-cell Carcinoma[J].Int J Cancer,2000, 86(3):429-435.
[13] Bosch FX, Burchell AN, Schiffman M, et al.Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia[J].Vaccine,2008, 26( Suppl 10): K1-16.